Skip to main content

Table 1 Score values, level of significance, and questionnaires used in all cross-over studies analyzed

From: Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer

Reference Questionnaires Values, Level of significance, and Statistical tests
#3 STAI (trait anxiety)
BDI
-STAIa: 1-month follow-up: baseline: 43; 1 month: 36; t11 = 4.36, P = .001; 3-month follow-up: 3 months: 37; t10 = 2.55, P = .03
-BDIa: 6-month follow-up: baseline: 16; 6 months: 7; t7 = 2.71, P = .03
-t tests
#4 STAI (state anxiety) 2-month follow-up: baseline: mean (SD) 53.1 (4.7); 2 months: 41.5 (3.2); P = .021 (F = 4.846, df = 2.18
-Repeated-measures analysis of variance (ANOVA) corrected for multiplicity
#6 BDI
BSI
GRID
HADS
HAM-A
POMS
STAI
5-week follow-up
-BDI - low dose: baseline: 18.40 (1.09), 5 weeks: 12.92 (1.58); high dose: baseline: 17.77 (1.61), 5 weeks: 7.00 (1.39); P < .05; difference between doses: P < .01
-BSI - low dose: baseline: 41.76 (4.40), 5 weeks: 33.74 (4.47); high dose: baseline: 40.19 (3.71), 5 weeks: 18.08 (3.62); P < .05; difference between doses: P < .01
-GRID - low dose: baseline (mean (SD)): 22.32 (0.88), 5 weeks: 14.80 (1.45); high dose: baseline: 22.84 (0.97), 5 weeks: 6.64 (1.04); P < .05; difference between doses: P < .001
-HADS - low dose: baseline: 9.48 (0.71), 5 weeks: 6.04 (0.79); high dose: baseline: 9.81 (0.69), 5 weeks: 3.92 (0.74); P < .05; difference between doses: P < .05
-HAM-A - low dose: baseline: 25.68 (0.89), 5 weeks: 16.64 (1.53); high dose: baseline: 25.73 (1.11), 5 weeks: 8.48 (1.16); P < .05; difference between doses: P < .001
-POMS - significant difference observed only with the high dose (baseline: 56.93 (5.33), 5 weeks: 18.96 (5.78); P < .05) and among doses (P < .01)
-STAI - low dose: baseline: 47.46 (1.62), 5 weeks: 40.48 (2.11); high dose: baseline: 47.73 (1.91), 5 weeks: 34.64 (1.84); P < .05; difference between doses: P < .05
− 6-month follow-upb:
-BDI: 8.00 (1.50), 6.17 (1.26); P < 0.001
-BSI: 4.64 (0.72), 3.46 (0.66); P < 0.001
-GRID: 6.95 (1.24), 6.23 (1.30); P < 0.001
-HADS: 4.64 (0.72), 3.46 (0.66); P < 0.001
-HAM-A: 7.95 (1.19), 7.04 (1.17); P < 0.001
-POMS: 23.50 (6.57), 12.52 (5.36); P < 0.001
STAI: 36.83 (2.08), 35.32 (2.18); P < 0.001
-z-tests
#7 BDI
HADS
STAI
-BDI: P.01 (1 day, 2 and 6 weeks), P < .05 (7 and 26 weeks)
-HADS Anxiety: P < .05 (1 day and 26 weeks), P.01 (2, 6, and 7 weeks)
-HADS Depression: P.001 (1 day and 6 weeks), P < .01 (2 and 7 weeks), P < .05 (26 weeks)
-HADS Total: P.001 (1 day, 2, 6 and 7 weeks), P < .05 (26 weeks)
-STAI State: P.01 (1 day and 7 weeks), P.001 (2 and 6 weeks), P < .05 (26 weeks)
-STAI Trait: P.01 (1 day), P.001 (2, 6 and 7 weeks), P < .05 (26 weeks)
-t-tests (P values for 1 day and 2, 6, and 7 weeks pre-crossover, and for 26 weeks post-crossover)
  1. BDI Beck Depression Inventory, BSI Brief Symptom Inventory, GRID GRID-Hamilton Depression Rating Scale, HADS Hospital Anxiety and Depression Scale, HAM-A Hamilton Anxiety Rating Scale, POMS Profile of Mood States, STAI State-Trait Anxiety Inventory
  2. aThese values are approximate, based on visual inspection of the graphics, since the values are not given in the original text
  3. bValues represent mean (SD) for low-dose-1st/high-dose-2nd versus high-dose-1st/low-dose-2nd)